UniPharma Co., Ltd. (TPEX:6621)
Taiwan
· Delayed Price · Currency is TWD 12.45
0.00 (0.00%)
Mar 10, 2026, 1:55 PM CST
UniPharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 90.79 | 93.46 | 103.22 | 128.11 | 105.39 | 138.64 | Upgrade
|
| Revenue Growth (YoY) | -8.81% | -9.46% | -19.43% | 21.56% | -23.98% | -10.14% | Upgrade
|
| Cost of Revenue | 43.23 | 44.75 | 52.21 | 53.49 | 46.06 | 69.32 | Upgrade
|
| Gross Profit | 47.55 | 48.71 | 51.02 | 74.62 | 59.33 | 69.32 | Upgrade
|
| Selling, General & Admin | 66.36 | 62.96 | 60.49 | 69.18 | 66.5 | 65.07 | Upgrade
|
| Research & Development | 21.23 | 16.57 | 17.83 | 26.32 | 33.05 | 24.86 | Upgrade
|
| Operating Expenses | 87.58 | 79.53 | 78.32 | 95.5 | 99.55 | 89.93 | Upgrade
|
| Operating Income | -40.03 | -30.82 | -27.31 | -20.88 | -40.22 | -20.61 | Upgrade
|
| Interest Expense | -0.11 | -0.11 | -0.01 | -0.04 | -0.1 | -0.14 | Upgrade
|
| Interest & Investment Income | 2.01 | 1.95 | 1.97 | 1.26 | 1.24 | 1.53 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.89 | 1.15 | -0.05 | 0.97 | -0.21 | -0.45 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.24 | 3.06 | 3.59 | 0.96 | 1.28 | 1.6 | Upgrade
|
| EBT Excluding Unusual Items | -38.78 | -24.78 | -21.81 | -17.74 | -38.02 | -18.07 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.05 | -0.04 | - | 10.71 | - | 1.77 | Upgrade
|
| Asset Writedown | - | - | - | - | -36.43 | -39.05 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.04 | - | Upgrade
|
| Pretax Income | -38.84 | -24.82 | -21.81 | -7.03 | -74.41 | -55.35 | Upgrade
|
| Earnings From Continuing Operations | -38.84 | -24.82 | -21.81 | -7.03 | -74.41 | -55.35 | Upgrade
|
| Minority Interest in Earnings | - | - | - | 0.58 | - | - | Upgrade
|
| Net Income | -38.84 | -24.82 | -21.81 | -6.45 | -74.41 | -55.35 | Upgrade
|
| Net Income to Common | -38.84 | -24.82 | -21.81 | -6.45 | -74.41 | -55.35 | Upgrade
|
| Shares Outstanding (Basic) | 36 | 36 | 36 | 35 | 35 | 35 | Upgrade
|
| Shares Outstanding (Diluted) | 36 | 36 | 36 | 35 | 35 | 35 | Upgrade
|
| Shares Change (YoY) | - | - | 0.04% | 0.81% | - | -0.05% | Upgrade
|
| EPS (Basic) | -1.09 | -0.70 | -0.61 | -0.18 | -2.11 | -1.57 | Upgrade
|
| EPS (Diluted) | -1.09 | -0.70 | -0.61 | -0.18 | -2.11 | -1.57 | Upgrade
|
| Free Cash Flow | -20.29 | -15.11 | 3.92 | -32.09 | -13.54 | -17.71 | Upgrade
|
| Free Cash Flow Per Share | -0.57 | -0.43 | 0.11 | -0.90 | -0.39 | -0.50 | Upgrade
|
| Gross Margin | 52.38% | 52.12% | 49.42% | 58.25% | 56.29% | 50.00% | Upgrade
|
| Operating Margin | -44.09% | -32.98% | -26.45% | -16.30% | -38.16% | -14.87% | Upgrade
|
| Profit Margin | -42.78% | -26.56% | -21.13% | -5.03% | -70.60% | -39.93% | Upgrade
|
| Free Cash Flow Margin | -22.35% | -16.17% | 3.80% | -25.05% | -12.85% | -12.78% | Upgrade
|
| EBITDA | -36.73 | -27.49 | -24.99 | -18.8 | -34.99 | -15.17 | Upgrade
|
| EBITDA Margin | -40.46% | -29.42% | -24.21% | -14.68% | -33.20% | -10.94% | Upgrade
|
| D&A For EBITDA | 3.3 | 3.33 | 2.32 | 2.07 | 5.23 | 5.45 | Upgrade
|
| EBIT | -40.03 | -30.82 | -27.31 | -20.88 | -40.22 | -20.61 | Upgrade
|
| EBIT Margin | -44.09% | -32.98% | -26.45% | -16.30% | -38.16% | -14.87% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.